Illumina, Inc. $ILMN Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lessened its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 21.4% during the third quarter, HoldingsChannel reports. The institutional investor owned 746,778 shares of the life sciences company’s stock after selling 203,293 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Illumina were worth $204,378,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the business. Baker Tilly Wealth Management LLC lifted its stake in Illumina by 3.3% during the third quarter. Baker Tilly Wealth Management LLC now owns 1,297 shares of the life sciences company’s stock worth $355,000 after purchasing an additional 42 shares during the period. Ashton Thomas Securities LLC grew its position in Illumina by 3.3% during the third quarter. Ashton Thomas Securities LLC now owns 1,348 shares of the life sciences company’s stock worth $369,000 after buying an additional 43 shares in the last quarter. Elevation Wealth Partners LLC raised its stake in Illumina by 19.7% in the third quarter. Elevation Wealth Partners LLC now owns 292 shares of the life sciences company’s stock valued at $80,000 after purchasing an additional 48 shares in the last quarter. Evergreen Capital Management LLC increased its holdings in Illumina by 0.5% in the 3rd quarter. Evergreen Capital Management LLC now owns 9,474 shares of the life sciences company’s stock valued at $2,593,000 after buying an additional 50 shares during the period. Finally, Pinnacle Associates Ltd. raised its position in shares of Illumina by 2.2% in the 3rd quarter. Pinnacle Associates Ltd. now owns 2,506 shares of the life sciences company’s stock valued at $686,000 after buying an additional 54 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Illumina reported third-quarter adjusted EPS of $1.44, above the $1.36 consensus estimate, while revenue increased 4.2% year over year to approximately $1.13 billion. Illumina Reports Financial Results for Third Quarter
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 outlook, with revenue guidance of roughly $4.65 billion at the midpoint, supported by clinical sequencing demand and continued adoption of the NovaSeq X platform. ILMN Q3 Earnings Call Highlights
• Positive Sentiment: Long-term industry demand remains favorable. Recent market reports point to strong growth in clinical genomics, sequencing-as-a-service, population screening, and AI-enabled genomic analysis—markets in which Illumina is a major participant. These reports are industry forecasts rather than new company contracts or financial commitments.
• Neutral Sentiment: Analyst sentiment became more cautious. JPMorgan reduced its price target from $320 to $300, while Robert W. Baird maintained a Hold rating. The target cut suggests less near-term upside following Illumina’s substantial prior rally. JPMorgan Adjusts Price Target
• Negative Sentiment: Revenue performance disappointed investors. Although earnings surpassed estimates, quarterly revenue was below consensus in several reports, highlighting softer demand than expected and limiting the impact of the profit beat.
• Negative Sentiment: China exposure, tariffs, and business mix remain concerns. Investors are worried about China-related revenue challenges, tariff uncertainty, research-market weakness, and pricing pressure. A broader pullback in AI-linked technology stocks also hurt sentiment toward Illumina. Illumina Shares Tumble on China Woes

Wall Street Analyst Weigh In

Several brokerages have issued reports on ILMN. TD Cowen increased their price target on Illumina from $210.00 to $270.00 and gave the stock a “hold” rating in a report on Tuesday, October 13th. Stephens lowered shares of Illumina from an “overweight” rating to an “equal weight” rating and set a $275.00 target price for the company. in a report on Friday, October 23rd. Canaccord Genuity Group boosted their price target on Illumina from $205.00 to $300.00 and gave the stock a “hold” rating in a research report on Monday, October 19th. Piper Sandler lifted their price objective on Illumina from $225.00 to $305.00 and gave the company an “overweight” rating in a research report on Monday, September 28th. Finally, Evercore reiterated an “underperform” rating on shares of Illumina in a research note on Friday. Nine research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Illumina currently has a consensus rating of “Hold” and an average price target of $238.53.

Insider Buying and Selling at Illumina

In other Illumina news, Director Keith Meister sold 119,501 shares of the company’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $218.40, for a total value of $26,099,018.40. Following the transaction, the director directly owned 770,350 shares in the company, valued at $168,244,440. This represents a 13.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Christensen Wedel sold 1,033 shares of Illumina stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the sale, the senior vice president directly owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 2,061,235 shares of company stock valued at $436,356,102. Corporate insiders own 2.90% of the company’s stock.

Illumina Price Performance

Shares of ILMN opened at $235.99 on Monday. The stock has a market capitalization of $35.63 billion, a price-to-earnings ratio of 40.62, a price-to-earnings-growth ratio of 3.30 and a beta of 1.46. Illumina, Inc. has a 1 year low of $106.12 and a 1 year high of $309.35. The business’s 50 day simple moving average is $249.30 and its 200-day simple moving average is $176.18. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.63 and a quick ratio of 2.05.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The company had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.15 billion. During the same period in the previous year, the firm posted $1.34 earnings per share. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. As a group, equities analysts expect that Illumina, Inc. will post 5.43 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.